newsfilter
← Latest News
GlobeNewswire·

Calyxt, Inc., Cellectis' Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial Results

NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that Calyxt, Inc. (NASDAQ:CLXT),